VEN elderly CLL 2019 final BJH BJH-2019-01315 R2.pdf (283.28 kB)
Download file

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia

Download (283.28 kB)
journal contribution
posted on 20.03.2020, 11:22 by Harriet S Walter, TA Eyre, LE Roeker, C Fox, S Gohill, R Walewska, F Forconi, A Arumainathan, D Brander, J Allan, S Schuster, B Hill, F Lansigan, B Cheson, N Lamanna, C Coombs, P Barr, A Skarbnik, M Shadman, C Ujjani, L Pearson, J Pagel, R Jacobs, A Mato, A Broom
Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton's tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B‐cell lymphoma 2 inhibitor venetoclax. We provide a comprehensive analysis of key safety measures and efficacy in 342 patients comparing age categories ≥75 and <75 years treated in the relapsed, refractory non‐trial setting. We demonstrate that venetoclax has equivalent efficacy and safety in relapsed/refractory CLL patients who are elderly, the majority of whom are previous ibrutinib‐exposed and therefore may otherwise have few clear therapeutic options.

Funding

Oxford NIHR Biomedical Research Centre

History

Citation

British Journal of Haematology, 2019, 188, 6, pp. 918-923

Author affiliation

Cancer Research Centre

Version

AM (Accepted Manuscript)

Published in

British Journal of Haematology

Volume

188

Issue

6

Pagination

918-923

Publisher

Wiley

issn

0007-1048

eissn

1365-2141

Acceptance date

09/09/2019

Copyright date

2019

Publisher version

https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.16271

Language

en

Usage metrics

Categories

Exports